Beyond PD-L1: How the I3LUNG Consortium Validated Multimodal AI in 2,365 Advanced Lung Cancer Patients
DDDr. Dereck Mush, MD, MBA
Sep 15
ImpriMed
Live-cell testing and multimodal AI for precision oncology and drug-development decisions.
What they do
ImpriMed combines ex vivo assays of patient-derived cancer cells with genomic, immunophenotypic and clinical data. Its $10 million Series A2 bridge, led by LB Investment, supports US commercialization and expansion in Asia.
The record
- Vertical
- Oncology
- Sub-segment
- Functional precision medicine
- Product type
- Diagnostics
- Stage
- Series A
- Headquarters
- Palo Alto, CA, USA
- Region
- North America
- Founded
- 2017
- Total funding
- $33M raised
Notable investors: LB Investment, NAVER D2SF, Samsung Securities, Alois Ventures.
Also in Oncology
Related on The Signal
Breaking the PMA Bottleneck: How FDA's Class II Reclassification Accelerates Precision Oncology
DDDr. Dereck Mush, MD, MBA
Sep 16
The $1 Billion Bet on Pre-Symptomatic Medicine: Who Will Own the Longitudinal Baseline?
DDDr. Dereck Mush, MD, MBA
Sep 13
Unlocking Orphan Neuromuscular Indications: Why IntraBio's Aqneursa Approval Signals a Regulatory Re-evaluation of Small-Cohort Crossover Trials
DDDr. Dereck Mush, MD, MBA
Sep 22